Boston Scientific Corp (BSX)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	9,896,000	9,549,000	9,314,000	9,005,000	8,727,000	8,650,000	8,491,000	8,390,000	8,177,000	7,730,000	7,488,000	6,568,000	6,447,000	6,793,000	6,933,000	7,594,000	7,620,000	7,398,000	7,188,000	7,066,000
Revenue (ttm)	US$ in thousands	13,974,000	10,508,000	10,348,000	9,999,000	9,228,000	12,104,000	11,689,000	11,502,000	11,625,000	11,168,000	10,855,000	9,774,000	9,553,000	9,751,000	9,790,000	10,420,000	10,349,000	10,035,000	9,758,000	9,649,000
Gross profit margin		70.82%	90.87%	90.01%	90.06%	94.57%	71.46%	72.64%	72.94%	70.34%	69.22%	68.98%	67.20%	67.49%	69.66%	70.82%	72.88%	73.63%	73.72%	73.66%	73.23%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $9,896,000K ÷ $13,974,000K
= 70.82%

Boston Scientific Corp.'s gross profit margin has remained relatively stable over the past eight quarters, ranging from 68.81% to 69.49%. This consistency indicates the company's ability to effectively manage its production costs and maintain a healthy markup on its products. The gradual improvement in the gross profit margin from Q4 2022 to Q4 2023 suggests that Boston Scientific Corp. may have implemented operational efficiencies or pricing strategies that have positively impacted its profitability. Overall, the consistent and solid gross profit margin performance reflects positively on the company's operational effectiveness and ability to generate profits from its core business activities.